Non-cardiogenic Ischemic Stroke
Conditions
Interventions
Group 1 :Subcutaneous injection of elouximab and Atorvastatin calcium tablets 40 mg orally
Group 2:Atorvastatin calcium tablets 40 mg orally
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. 18 <= age <= 80; 2. Patients with acute non-cardiogenic cerebral infarction within 24 hours of onset; 3. Unconscious disturbance; 4. For patients with the first onset or previous cerebral infarction patients without sequelae such as limb paralysis, the NIHSS score will not be affected; the previous mRS score is <= 1 point; 5. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Hemorrhagic stroke or mixed stroke; 2. Brain arteriovenous malformation or intracranial tumor; 3. Cardiogenic cerebrovascular disease; 4. Patients with uncontrollable severe hypertension, severe infection or abnormal liver function, renal insufficiency, blood system diseases with bleeding tendency, etc.; 5. History of previous cerebral hemorrhage; 6. Retinal hemorrhage or visceral hemorrhage within 30 days; 7. Patients who used PCSK9 inhibitors 3 months before the onset; 8. Patients with disturbance of consciousness; 9. Patients allergic to atorvastatin and PCSK9 inhibitors; 10. Patients who have had adverse reactions to atorvastatin in the past; 11. Pregnant or lactating women; 12. Those who are considered by the researchers to be inappropriate to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| early neurological deterioration; | — |
Countries
China
Contacts
Public ContactXiaofei Ji
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed